key: cord-1048425-mq5kgr13
authors: Elayeete, Sarah; Nampeera, Rose; Nsubuga, Edirisa Juniour; Nansikombi, Hildah Tendo; Kwesiga, Benon; Kadobera, Daniel; Amanya, Geofrey; Ajambo, Miriam; Mwanje, Wilbrod; Riolexus, Alex Ario; Harris, Julie R.
title: Comparative Epidemiologic Analysis of COVID-19 Patients during the First and Second Waves of COVID-19 in Uganda
date: 2022-03-24
journal: IJID Regions
DOI: 10.1016/j.ijregi.2022.03.017
sha: e70505bf061913b9ae2af448a9e61c7030f6a3ca
doc_id: 1048425
cord_uid: mq5kgr13

Introduction Uganda has been affected by two major waves of COVID-19. The first wave occurred during late 2020 and the second wave in late April 2021. We compared epidemiologic characteristics of hospitalized (HP) and non-hospitalized COVID-19 patients (NHP) during the two COVID-19 waves in Uganda. Methods We defined ‘Wave 1’ as November-December, 2020, and ‘Wave 2’ as April-June, 2021. A total of 800 patients were included in the study. We collected medical record data for HP (200 for each wave). We retrieved contact information for PCR-confirmed NHP (200 for each wave) from lab records and interviewed them by phone. Findings A higher proportion of HP in Wave 1 than Wave 2 were male (73% vs. 54%, p=0.0001). More HP in Wave 2 than Wave 1 had severe disease or died (65% vs. 31%, p<0.0001). NHP in Wave 2 were non-significantly younger than those in Wave 1 (mean age 29 vs. 36 years, p=0.13). HP were significantly older than NHP in Wave 2 (mean age 48 vs. 29 years, p<0.0001), but not Wave 1 (mean age 48 vs. 43 years, p=0.31). Interpretation Demographic and epidemiologic characteristics of hospitalized and non-hospitalized patients between and within Waves 1 and 2 of the COVID-19 in Uganda differed. Funding No funding was obtained for data analysis and the development of this manuscript.

We searched PubMed for research articles published in English from March 21, 2020 to April 28, 2021, using the terms "SARS-CoV-2", "COVID-19", "wave", "hospitalization", "mortality", and/or "variants". We found 45 articles on these topics. The SARS-CoV-2 Delta variant has been shown to be more transmissible and associated with more severe disease than earlier SARS-CoV-2 variants (Fisman and Tuite 2021, Sheikh, McMenamin et al. 2021) . At the time this study was conducted, little was known about the Delta variant; however, media reports suggested that it might cause more severe disease in younger persons (CN 2021 , UN 2021 .

The second wave of SARS-CoV-2 infections in Uganda was caused primarily by the Delta variant, while the first wave was caused by a mixture of non-Delta variants (CDC 2021) . We found that infections in the first and second waves in Uganda differed across several indicators. Hospitalized patients were more likely to be male in the first wave than the second wave. Non-hospitalized patients were younger in the second wave than the first wave. Increasing age was strongly associated with hospitalization during the second wave, but only marginally associated with hospitalization in the first wave. A higher proportion of hospitalized patients had severe disease and died in the second wave than the first.

Different SARS-CoV-2 variants may have differing epidemiologic characteristics. Our findings emphasise the need to independently study and understand the epidemiologic 6 characteristics of each SARS-CoV-2 variant to ensure messaging and preparedness in each wave are tailored appropriately. 7

Uganda reported its first case of COVID-19 on March 21, 2020 (WHO 2020 . After several months with few confirmed cases, cases began increasing in August, and a large wave swept through the country in late 2020 (Kadowa 2020) . The number of cases waned in early 2021, but a resurgence began in April 2021. The second wave peaked in June and continued through mid-August 2021. It expanded more quickly than the first wave and challenged the capacity of the healthcare system (Blair 2021 , Bugembe, Phan et al. 2021 ).

The first Delta variant sequences in Uganda were detected in mid-April 2021. From mid-May through at least early September 2021, nearly all SARS-CoV-2 isolates sequenced in Uganda have been Delta variant (Bugembe, Phan et al. 2021) .

During March 2021, shortly before the start of the second wave of infections in Uganda, the country launched a mass COVID-19 vaccination program using the AstraZeneca vaccine ChAdOx1-S (africanews 2021, VOA 2021). However, vaccine uptake was slow, and as of June 2021, only 750,000 of the 44 million people across the country had been vaccinated, including 713,000 receiving the first dose and 36,000 receiving both doses of vaccine.

Like many areas of the world, Uganda has been affected by misinformation about COVID-19, frequently spread through social media. Mistrust and suspicion surrounded the rollout of COVID-19 vaccines in the country (Kasozi, MacLeod et al. 2020 , Samarasekera 2021 , and social media messages about the dangers of vaccination were rampant during the rollout, including reports that younger (CN 2021 , UN 2021 , fully vaccinated persons were dying in hospitals. There was an urgent need to gather data about the epidemiologic characteristics and vaccination status of patients in the second wave, both to support evidence-based public communication, and to provide relevant, current data about infections in Uganda. We compared the epidemiologic characteristics of hospitalized patients (HP) and nonhospitalized patients (NHP), including vaccination status, diagnosed during the first and second waves of COVID-19 in Uganda.

The study included hospitalized patients (HP) at the two highest-volume referral hospitals in Uganda, Mulago Hospital in Kampala and Entebbe Grade B Hospital in Entebbe. We also included non-hospitalized patients (NHP) from throughout the country.

The study procedures took place during May-June 2021. We defined our study periods as 'Wave 1' (November-December 2020) and 'Wave 2' (April-June 2021). Although neither of these periods fully encompassed the waves of interest, we selected the Wave 1 period to cover the months during which the highest number of patients were identified. We selected the Wave 2 period to include all patients with confirmed infection from April 2021 up through the start of our investigation.

We calculated a sample size that would be needed to identify a difference of 5 years in mean age between patients in each study group. At 80% power and 95% confidence, and a standard deviation of 15 years, 200 patients were needed in each group (HP in Wave 1, HP in Wave 2, NHP in Wave 1, and NHP in Wave 2), for a total of 800 patients.

In each of the two hospitals, we collected demographic and clinical data for 100 HP in Wave 1 and 100 HP in Wave 2, for a total of 400 HP. In addition, we collected data for 200 NHP during Wave 1 and 200 during Wave 2 (Figure 1a-d) .

For HP, we separated all patient files in each hospital for the periods of interest and sorted by date, then systematically sampled using a sampling interval to reach 100 patients from each hospital in each wave.

For NHP, we identified case-patients from the national case line list. While the national case line list included patients from all areas of Uganda, the majority of confirmed case-patients identified in Uganda [14,646/22,768 (64%) during November 1-December 30, 2020 and 23,791/32,477 (73%) during April 1-June 20, 2021 (when this study was started)] were from the Greater Kampala Metropolitan Area. We created a sampling frame for each wave and selected 200 NHP per wave using a random number generator.

We abstracted data from hospital records for HP. We retrieved contact information for NHP from the national case line list and interviewed them by phone to collect demographic and clinical information. Any patient who was contacted and found to have been hospitalized (n=8) was dropped and randomly replaced.

Patient disease status was categorized as asymptomatic, mild/moderate, severe/critical, or died. Asymptomatic infections comprised patients with no symptoms of COVID-19 disease.

Mild/moderate disease included patients with symptoms, but without shortness of breath during clinical assessments; where clinical assessments were available, we defined it as patients with symptoms but with oxygen saturation >94% on atmospheric air. Severe/critical disease was defined as patients with oxygen saturation (SpO2) <94% on room air, ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) <300, >30 breaths/min, or lung infiltrates >50%, respiratory failure, septic shock, and/or multiple organ dysfunction. Deaths were counted only among persons hospitalized for their COVID-19 infection who died before recovery. Full vaccination was defined as receiving two doses of vaccine at least 14 days before illness onset or positive test.

We calculated means and interquartile range (IQR) for continuous variables and frequencies and odds ratios with 95% confidence intervals (CI). We also compared between-and withinwave statistics using a two-sample t-test. Mean age was compared using the independent samples T-test. We used logistic regression to assess the factors associated with hospitalization and death for COVID-19 patients. Data were analysed using Epi Info version 7.2.

Among 400 HP, 255 (64%) were male. The mean age was 46 years (range, 0-98). Nearly half (182; 46%) of HP had an underlying condition, with hypertension being the most common (108; 27%). Among 400 NHP, 219 (55%) were male. The mean age was 32 years (range, 0-82). Within-wave differences in hospitalized and non-hospitalized patients, Waves 1 and 2 of COVID-19, Uganda, 2020 In Wave 1, HP were more likely than NHP to be male (73% vs. 58%, p=0.002), but in Wave 2, HP were as likely as NHP to be male (54% vs. 52%, p=0.69) ( Table 1) . HP were significantly older than NHP in Wave 2 (mean age 48 vs 29 years, p=0.0001) but not in Wave 1 (mean age 48 vs 43 years, p=0.31). As vaccines only became available during March 2021, only patients in Wave 2 had received any vaccine. No patients were fully vaccinated at their time of illness onset ( Table 2) . COVID-19, Uganda, 2020 HP in both waves were more often male than female (Table 1) . However, HP in Wave 1 were much more frequently male than HP in Wave 2 (73% vs. 54%, p<0.0001). HP were asymptomatic about half as frequently in Wave 2 as HP in Wave 1 (10% vs 18%, p=0.02), and died more than four times as often (26% vs. 6%, p<0.0001) ( Table 2) . COVID-19 infection, Uganda, 2020 While NHP were more likely to be male than female in both Waves 1 and 2, the difference in the proportion male between waves was not significant (58% male in Wave 1 vs 52% male in Wave 2, p=0.23) ( Table 1) . NHP were non-significantly younger in Wave 2 than in Wave 1 (mean age: 29 vs. 36 years, p=0.13). A non-significantly higher proportion of NHP had any symptoms in Wave 2 vs. Wave 1 (59% vs 51%, p=0.11) ( Table 2) .

Male sex was associated with two-fold increased odds of hospitalization in Wave 1 (p<0.001), but not in Wave 2 (p=0.62) ( Table 3) . Male sex was also associated with two-fold increased odds of death in Wave 2 (p=0.04) but not Wave 1 (p=0.9) ( Table 4 ). Being aged 6-19 years was associated with reduced odds of hospitalization in both Wave 1 and Wave 2, compared to being aged 20-34 years. Being aged 55 years or older was associated with 28fold increased odds of hospitalization in Wave 2 (p<0.0001) but was only associated with a 2-fold increased odds of hospitalization in Wave 1 (p=0.05). Hypertension and diabetes were more strongly associated with hospitalization in both waves than age, though there was an additive effect of age, hypertension, and diabetes in increasing the odds of hospitalization in Wave 2 (Table 3) . Among the 31 partially vaccinated persons in Wave 2, there was no significant association with hospitalization risk (p=0.10). Increasing age was associated with increased mortality in both waves (p<0.0001) even among persons without comorbidities (p=0.002) (Table 4 ).

We found that the first and second waves of COVID-19 in Uganda, caused by distinct SARS-CoV-2 variants, differed across epidemiologic metrics. Hospitalized patients were more often male in Wave 1 than in Wave 2. Non-hospitalized patients in Wave 2 were younger than those in Wave 1, while hospitalized patients were older. Age was strongly associated with hospitalization during Wave 2 but not Wave 1, and disease was more severe in Wave 2.

Older age was associated with death in both Wave 1 and Wave 2, but the strength of association was much stronger in Wave 1. These findings indicate that new SARS-CoV-2 variants may have different epidemiologic characteristics from previous variants and should be studied independently to ensure messaging and preparedness in each wave are tailored appropriately.

The sex bias in COVID-19 has been well-described and it is generally accepted that males with COVID-19 are at increased risk of severe disease and death compared with females (Peckham, de Gruijter et al. 2020 , Gomez, Du-Fay-de-Lavallaz et al. 2021 , Viveiros, Rasmuson et al. 2021 . Innate and adaptive immune responses have been suggested to be responsible for the 'female advantage' with COVID-19 (Pradhan and Olsson 2020), as have sex hormones (Chakravarty, Nair et al. 2020) . However, in our study, this association of sex with the hospitalization group was only true for patients in Wave 1, and not Wave 2. In addition, despite the association between male sex and hospitalization in Wave 1, male sex was only associated with death in Wave 2. This might be due to the relatively small number of deaths among hospitalized patients in Wave 1, compared to Wave 2.

Hypertension and diabetes were strongly associated with hospitalization in both waves. In part, this may be a result of national recommendations around clinical management of persons with COVID-19 in Uganda (National-guidelines 2020). Throughout the pandemic, persons with asymptomatic SARS-CoV-2 infection in Uganda and with underlying conditions predisposing them to more severe disease have been encouraged to enter the hospital for observation (Kirenga, Muttamba et al. 2020) . This is largely due to challenges with obtaining rapid access to advanced healthcare in some areas of Uganda (Dowhaniuk 2021) . However, this practice became less common after home-based care for COVID-19 patients was established during late 2020 (Independent 2020) . Because of this, identifying the association between underlying conditions and death is likely to be more appropriate as a metric of disease severity in this setting than their association with hospitalization. Despite this, while hypertension was associated with a greater proportion of death in both waves, only the combination of hypertension and diabetes in Wave 2 showed a statistically significant association with death. Systematic reviews have identified both hypertension and diabetes to be modestly associated with death(de Almeida-Pititto 2020) . Our sample size may have been insufficient to detect an association between these underlying diseases and hypertension in Wave 1, if it exists.

National and social media reports in Uganda during the second wave often stated that more young persons were being hospitalized than in the previous wave (CN 2021). In addition, media reports elsewhere have suggested that younger persons might be more affected by the Delta variant than by previous variants (Bloomberg 2021 , Carolinapress 2021 , Healthline 2021 , UN 2021 . Our data did not substantiate reports of more severe disease among younger persons with the Delta variant. In contrast, we found that the median age of hospitalized patients was older in Wave 2 than Wave 1, while the mean age of non- in Uganda, universities reopened and 'semi-candidate' classes were restarted. At this time, reports of outbreaks in schools began to increase markedly (Eyeradio 2021) , with nearly 1,000 cases in 43 schools reported by mid-June. Following holiday school closures in late April, during which parents went to retrieve their children from boarding schools and universities that had closed for holiday, cases were also reported among their family members (Eyeradio 2021 , University-world-news 2021 . Anecdotally, children returning home often infected their parents. This is plausible as the cause of an increase in the proportion of cases in the school-aged group as well as persons in their parents' age groups (Dispatch 2021) .

Hospitalized patients in Wave 2 were twice as likely to have severe or critical disease or die as those in Wave 1, this has also been noted in previous studies in Scotland (Sheikh, McMenamin et al. 2021 ). This may be partly attributed to the older age of patients in Wave 2, who may have had more comorbidities or weaker immune responses compared with hospitalized patients in Wave 1 as reported in the April 2020 survey, and in two metaanalysis studies (Kasozi, MacLeod et al. 2020 , Singhal, Kumar et al. 2021 . However, some studies suggest that, it may reflect a different pathogenesis of the Delta variant, compared to earlier variants (Bager, Wohlfahrt et al. 2021 , Twohig, Nyberg et al. 2022 . One recent study suggests that the Delta variant is associated with a two-fold increased risk of hospitalization and an increased risk of severe illness among persons with co-morbidities, possibly due to increased viral load (Sheikh, McMenamin et al. 2021) .

In Uganda, the COVID-19 vaccine only became available between Waves 1 and 2, and only the AstraZeneca vaccine was available to the public (africanews 2021). While persons receiving vaccine were initially requested to wait 30 days between vaccination doses, this was later modified to 3 months, in part due to vaccine shortages (The-guardian 2021). As a result, no patients in Wave 2, hospitalized or not, were fully vaccinated at their time of disease onset. Since the time of conducting this study, it has been shown that many vaccines are less effective against the COVID-19 Delta variant at a single dose, compared with other variants (Amirthalingam, Bernal et al. 2021 ). We found a protective but nonsignificant association between partial vaccination and hospitalization. However, the partially vaccinated population comprised a very small proportion of the overall Wave 2 population, primarily due to low vaccination rates in Uganda at the time. A fuller investigation of this issue should be conducted as soon as possible to provide additional data about the impact of the vaccine in Uganda.

Our study had some limitations. First, because of the rapid nature of the study, only two hospitals, both in the Greater Kampala Metropolitan Area, were included. These hospitals often treat the most severe cases of COVID-19, and thus we cannot extrapolate these data to all hospitalized patients. In addition, hospitalized and non-hospitalized patients were selected from different sites, which might have resulted in confounding that is difficult to control, particularly with regard to age: persons living in Greater Kampala Metropolitan Area might be younger on average than persons from other areas of the country. However, this would have biased results towards the null, as we found hospitalized patients to be older, rather than younger than non-hospitalized patients. In addition, patients at referral hospitals in Kampala and Entebbe can come from any area in the country. Unfortunately, we did not have data on the district of residence of most patients and were unable to make a direct comparison with regard to this variable. Second, there were secular changes between Waves 1 and 2 that might have had an impact on care-seeking. Specifically, widespread publicity about the cost of hospitalization during Wave 1 might have dissuaded some people from seeking hospitalization in Wave 2 (VOA-News 2021). Third, home-based care in Uganda only began in late 2020, and was more well-established during Wave 2 than Wave 1.

Before home-based care was established, all 'high-risk' persons with confirmed SARS-CoV-2 infection, regardless of disease severity, were encouraged to enter the hospital for observation in case their situation rapidly deteriorated. While this was still in place during Wave 2, home-based care might have been increasingly used for such patients. This could account in part for differences in the frequency of asymptomatic or mild infection among hospitalized patients in Wave 1 and Wave 2. Fourth, the burden of cases in Wave 2 was greater than in Wave 1, and we cannot rule out differences in the quality of care due to overwhelmed health facilities. Among cases that died, we did not investigate the cause of death and so cannot evaluate whether or not issues such as oxygen shortages might have been more frequent in one wave versus the other. Fifth, we did not have sequencing data on the specific patients in our sample and cannot confirm how many of the Wave 2 patients -hospitalized or otherwise -were infected with the Delta variant. Selection of SARS-CoV-2 isolates for sequencing in Uganda has been non-systematic, and samples in different sequencing periods have come from different areas of Uganda. While most of the Wave 2 patients in our study who were hospitalized or had samples taken after the third week of May 2021 (comprising 84% of our hospitalized and 90% of our non-hospitalized patients)

were almost certainly infected with the Delta variant, it isn't possible to estimate the proportion that were infected with the Delta variant before that time. Finally, our sample size was powered to detect differences in ages of hospitalized and non-hospitalized patients and thus we were not powered to identify specific clinical differences of importance.

Despite these limitations, the body of data included in this manuscript adds to the limited data available on the Delta variant of COVID-19. Additional data in larger studies are critical to supplement the data in this paper.

Demographic and epidemiologic characteristics of hospitalized and non-hospitalized patients between and within Waves 1 and 2 of the COVID-19 pandemic in Uganda differed.

New waves and variants of COVID-19 may not reflect the same characteristics as previous waves and should be studied independently.

This investigation was in response to a public health emergency and was therefore determined to be non-research. The Uganda Ministry of Health (MOH) gave the directive and approval to investigate rumours on hospitalization of vaccinated COVID-19 patients. We obtained verbal consent from HP, NHP, and next-of-kin for deceased patients. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. § §See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention. and JRH have verified the underlying data. All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication.

We declare no competing interests.

The dataset analysed for the manuscript is available upon request to the corresponding author: selayeete@musph.ac.ug 

Uganda. 

Uganda starts COVID-19 vaccinations

Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England

Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study

Variants in Africa: Recommendations for Preventing an Enduring Pandemic

What Makes Delta the Most Disruptive Virus Variant

Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda

Covid-19 Delta variant affects younger, unvaccinated populations in NC

CDC. ITF COVID-19 Dashboard Uganda Country Summary 2021

Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer

Young people suffer most in Uganda's second wave as country grapples with severe vaccine shortages

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis

Over 800 COVID-19 positive cases reported in schools across Uganda

Exploring country-wide equitable government health care facility access in Uganda

Museveni closes down schools, suspends gatherings as Coronavirus cases rise

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario

Sex Differences in COVID-19 Hospitalization and Mortality

People Make Up Biggest Group of Newly Hospitalized COVID-19 Patients

Health ministry releases COVID-19 home care guidelines

Health Ministry baffled by reports of COVID-19 cases in schools

Using evidence and analysis for an adaptive health system response to COVID-19 in Uganda

Misconceptions on COVID-19 Risk Among Ugandan Men: Results From a Rapid Exploratory Survey

Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda

National-guidelines-for-COVID-19

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Sex differences in severity and mortality from COVID-19: are males more vulnerable?

Feelings towards COVID-19 vaccination in Africa

Public Health Scotland and EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis

Ugandan minister blames west for Covid vaccine shortage

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Delta variant drives Africa COVID threat to 'whole new level´: WHO warns; 'dominant' in Europe by August

Universities close again amid surge in COVID cases

Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones

Court Orders Ugandan Government to Regulate COVID-19 Treatment Costs

Uganda to Begin Nationwide COVID Vaccinations Wednesday

WHO. COVID-19 in the WHO African Region